Rilimogene galvacirepvec-rilimogene glafolivec - BN ImmunoTherapeutics

Drug Profile

Rilimogene galvacirepvec-rilimogene glafolivec - BN ImmunoTherapeutics

Alternative Names: PROSTVAC; PROSTVAC-V-PROSTVAC-F; PROSTVAC-VF-TRICOM; PSA-TRICOM; Rilimogene gamvacirepvec-rilimogene glafolivec; Rilimogene-glafolivec-rilimogene-galvacirepvec; Vaccinia PSA TRICOM-fowlpox PSA TRICOM

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer BN ImmunoTherapeutics; National Cancer Institute (USA); University of California at San Francisco
  • Class Antineoplastics; Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 20 Oct 2017 National Cancer Institute plans a phase II trial of the combination of rilimogene galvacirepvec-rilimogene glafolivec, CV 301 and MSB 0011359C for Prostate cancer (Combination therapy) in USA (NCT03315871)
  • 14 Sep 2017 Bavarian Nordic terminates the phase III PROSPECT trial for Prostate cancer in USA, Australia, Belgium, Canada, Denmark, Estonia, France, Germany, Iceland, Israel, Poland, Puerto Rico, Russia, Spain, the Netherlands and United Kingdom as per the independent Data Monitoring Committee recommendation (NCT01322490)
  • 14 Sep 2017 An independent Data Monitoring Committee recommends discontinuation of the phase III PROSPECT trial in Prostate cancer based on a preplanned interim analysis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top